Coagulation Factor XI Activity Assay, Plasma
Factor XI (FXI) deficiency, historically referred to as hemophilia C, is an autosomal inherited bleeding disorder characterized by reduced activity of coagulation factor XI. Unlike hemophilia A and B, FXI deficiency rarely causes spontaneous bleeding. Instead, bleeding risk is typically provoked by trauma, surgery, or invasive procedures and shows marked interindividual variability. Severe deficiency is generally defined as FXI activity below approximately 15 IU/dL; however, clinical bleeding severity correlates poorly with factor activity levels. Some individuals with very low FXI activity may remain asymptomatic, whereas others experience significant hemorrhage. Bleeding risk is strongly influenced by the site of injury, with tissues that have high fibrinolytic activity, such as the oral cavity, nasal mucosa, tonsils, and genitourinary tract, being particularly susceptible. Menorrhagia may occur in affected women and is often influenced by coexisting hemostatic factors.
FXI deficiency can be classified into quantitative (CRM–) forms, in which both antigen and activity levels are reduced, and qualitative (CRM+) forms, in which antigen levels are normal but functional activity is impaired. Although rare in the general population, with an estimated prevalence of approximately 1 in 1,000,000 for severe disease, FXI deficiency is significantly more common among individuals of Ashkenazi Jewish descent due to founder mutations, most notably Glu117Stop (Type II) and Phe283Leu (Type III). Additional founder mutations have been identified in other populations, including French Basque and certain European groups. More than 180 pathogenic variants have been described in the F11 gene, affecting FXI secretion, dimerization, or enzymatic function. Because FXI circulates as a homodimer, some variants may exert dominant-negative effects, and nonsense mutations may lead to nonsense-mediated mRNA decay.
Acquired FXI deficiency is uncommon and may occur in association with liver disease, autoimmune disorders, malignancy, or exposure to plasma products, FXI concentrates, or Rh immunoglobulin, particularly in individuals with severe congenital deficiency. Acquired inhibitors should be suspected when FXI activity is low and the activated partial thromboplastin time (aPTT) fails to correct on mixing studies. Diagnosis is based on a prolonged aPTT with a normal prothrombin time (PT), confirmed by measurement of FXI activity. Antigen testing and molecular studies may assist with subtype classification, though genetic testing can be complex due to allelic heterogeneity.
- As an aid in the diagnosis of congenital or acquired factor XI deficiency or hemophilia C and assess disease severity
- Investigation of unexplained prolonged activated partial thromboplastin time when other intrinsic pathway deficiencies have been excluded
Adults: 55–150% Neonates: ≤10%
Platelet-poor plasma on 3.2% sodium citrate (Light-blue top) vial, 1 mL minimum.
Patient must not be receiving warfarin or heparin therapy.
Stability
- Ambient: 4 hrs.
- Refrigerated: unfavorable
- Frozen: 2 weeks